<DOC>
	<DOC>NCT02978573</DOC>
	<brief_summary>Evaluate and confirm the long-term safety and effectiveness of the Cartiva SCI implant established by the pivotal trial.</brief_summary>
	<brief_title>Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant in the Treatment of OA of the Great Toe</brief_title>
	<detailed_description>As part of the Conditions of Approval of Cartiva SCI for the treatment of first MTP osteoarthritis, the Food and Drug Administration (FDA) requires additional long term data to evaluate the long term safety and effectiveness of Cartiva including the durability and survivorship of the implant. This Post-Approval Study (PAS) addendum is intended to supplement the initial 24 months follow up period and provide additional long term safety and effectiveness data on Cartiva</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Subject must have been treated with Cartiva under MOTION study protocol PTC0031; and, Have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the IRB/Ethics Committee for longterm followup. Subjects who underwent a secondary surgical intervention to have the Cartiva implant removed during the 24month time period of participation in the MOTION study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>First MTP Joint</keyword>
	<keyword>Hallux Rigidus</keyword>
	<keyword>Hallux Limitus</keyword>
	<keyword>Cartilage Replacement</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>First MTP Joint Osteoarthritis</keyword>
	<keyword>Big Toe Pain</keyword>
</DOC>